These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27056241)

  • 41. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
    Robert C; Mateus C
    Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    Dagogo-Jack I; Lanfranchi M; Gainor JF; Giobbie-Hurder A; Lawrence DP; Shaw AT; Sullivan RJ
    J Immunother; 2017 Apr; 40(3):108-113. PubMed ID: 28221189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 44. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 45. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
    Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crystal-induced oligoarthritis triggered by pembrolizumab, an immune checkpoint inhibitor.
    Corominas H; Badlissi F; Shmerling RH
    Joint Bone Spine; 2018 Oct; 85(5):647-648. PubMed ID: 29414722
    [No Abstract]   [Full Text] [Related]  

  • 47. NICE guidance on pembrolizumab for advanced melanoma.
    Watson I; Dominguez PP; Donegan E; Charles Z; Robertson J; Adam EJ
    Lancet Oncol; 2016 Jan; 17(1):21-2. PubMed ID: 26621380
    [No Abstract]   [Full Text] [Related]  

  • 48. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.
    Sibaud V; David I; Lamant L; Resseguier S; Radut R; Attal J; Meyer N; Delord JP
    Melanoma Res; 2015 Dec; 25(6):555-8. PubMed ID: 26312439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.
    de Greef R; Elassaiss-Schaap J; Chatterjee M; Turner DC; Ahamadi M; Forman M; Cutler D; de Alwis DP; Kondic A; Stone J
    CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):5-7. PubMed ID: 27653180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 51. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
    Hansen E; Sahasrabudhe D; Sievert L
    Cancer Immunol Immunother; 2016 Jun; 65(6):765-7. PubMed ID: 27067877
    [No Abstract]   [Full Text] [Related]  

  • 52. Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age.
    Chanal J; Kramkimel N; Ratour C; Aractingi S; Guégan S; Avril MF
    Dermatology; 2019; 235(3):219-224. PubMed ID: 30721908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 54. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
    Carlos G; Anforth R; Chou S; Clements A; Fernandez-Peñas P
    Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
    Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
    [No Abstract]   [Full Text] [Related]  

  • 56. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
    Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
    Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
    [No Abstract]   [Full Text] [Related]  

  • 57. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 58. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 59. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.